AVEO Pharmaceuticals, Inc. (AVEO)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
AVEO Pharmaceuticals, Inc. (AVEO) trades at $15.00 with AI Score 69/100 (Buy). AVEO Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing cancer medicines. Market cap: 0, Sector: Healthcare.
Last analyzed: Feb 8, 2026AVEO Pharmaceuticals, Inc. (AVEO) Healthcare & Pipeline Overview
AVEO Pharmaceuticals is pioneering targeted cancer therapies, particularly with FOTIVDA for renal cell carcinoma, and a robust pipeline of oncology drugs. With strategic collaborations and a focus on unmet needs, AVEO aims to improve patient outcomes and establish a strong foothold in the biotechnology sector.
Investment Thesis
AVEO Pharmaceuticals presents a notable research candidate due to its focus on targeted cancer therapies and a diversified pipeline. FOTIVDA, approved for RCC, provides a revenue stream and a foundation for further growth. The company's gross margin of 87.8% indicates strong pricing power. Ongoing clinical trials for Ficlatuzumab and other pipeline candidates represent significant upside potential, particularly if these trials yield positive results. Strategic collaborations with established pharmaceutical companies further validate AVEO's technology and provide access to resources and expertise. While the company's P/E ratio is currently negative (-8.43) due to ongoing R&D investments, successful clinical development and commercialization of its pipeline could drive significant value creation.
Based on FMP financials and quantitative analysis
Key Highlights
- FOTIVDA approved for the treatment of renal cell carcinoma (RCC), providing a commercial foundation.
- Gross margin of 87.8% demonstrates strong pricing power and efficient operations.
- Pipeline includes Ficlatuzumab in Phase II trials for multiple cancer types, offering potential for expansion.
- Strategic collaborations with companies like AstraZeneca PLC and Novartis International Pharmaceutical Ltd. validate technology and provide resources.
- Negative P/E ratio of -8.43 reflects ongoing investment in R&D and clinical trials, with potential for future profitability.
Competitors & Peers
Strengths
- Approved product (FOTIVDA) generating revenue.
- Strong gross margin (87.8%).
- Diversified pipeline with multiple clinical-stage assets.
- Strategic collaborations with established pharmaceutical companies.
Weaknesses
- Negative P/E ratio indicating current unprofitability.
- Reliance on FOTIVDA for current revenue.
- High R&D expenses associated with drug development.
- Limited commercial infrastructure compared to larger pharmaceutical companies.
Catalysts
- Upcoming: Clinical trial results for Ficlatuzumab in squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia.
- Upcoming: Advancement of AV-203 and AV-380 into later-stage clinical trials.
- Ongoing: Potential for new strategic collaborations and partnerships.
- Ongoing: Expansion of FOTIVDA label to new indications or geographic markets.
Risks
- Potential: Clinical trial failures for pipeline candidates.
- Potential: Regulatory delays or non-approval of new therapies.
- Ongoing: Competition from other cancer therapies.
- Ongoing: Dependence on the success of FOTIVDA.
- Potential: Patent expirations and generic competition.
Growth Opportunities
- Expansion of FOTIVDA Label: AVEO has the opportunity to expand the label for FOTIVDA to include earlier lines of RCC treatment or combination therapies. This could significantly increase the addressable market for the drug. The market for RCC therapies is projected to reach $6 billion by 2028, providing a substantial opportunity for AVEO to grow its revenue. Success in expanding the label could occur within the next 2-3 years.
- Development of Ficlatuzumab: Ficlatuzumab, currently in Phase II trials for squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia, represents a significant growth opportunity. Positive clinical trial results could lead to regulatory approval and commercialization in multiple cancer indications. The market for head and neck cancer therapies is projected to reach $3 billion by 2027.
- Advancement of AV-203 and AV-380: AVEO's early-stage pipeline candidates, AV-203 and AV-380, offer potential for long-term growth. These therapies target novel pathways and could address unmet needs in cancer treatment and supportive care. Successful completion of Phase I trials and advancement into later-stage development could significantly increase the company's value. The timeline for commercialization is estimated at 5-7 years.
- Strategic Collaborations and Partnerships: AVEO can continue to pursue strategic collaborations and partnerships to expand its pipeline and commercial reach. Collaborations with larger pharmaceutical companies can provide access to resources, expertise, and global markets. These partnerships can accelerate the development and commercialization of AVEO's therapies and create additional value for shareholders. New partnerships could be forged within the next 1-2 years.
- Geographic Expansion: AVEO has the opportunity to expand its commercial operations into new geographic markets. Currently, FOTIVDA is marketed in the United States and Europe. Expanding into other regions, such as Asia and Latin America, could significantly increase the company's revenue and market share. This expansion could occur over the next 3-5 years, depending on regulatory approvals and market access.
Opportunities
- Expansion of FOTIVDA label to new indications.
- Positive clinical trial results for pipeline candidates.
- Further strategic collaborations and partnerships.
- Geographic expansion into new markets.
Threats
- Competition from other cancer therapies.
- Regulatory hurdles and potential delays in drug approvals.
- Clinical trial failures.
- Patent expirations and generic competition.
Competitive Advantages
- Proprietary drug formulations and intellectual property protection.
- Established clinical data and regulatory approvals for FOTIVDA.
- Strategic collaborations with leading pharmaceutical companies.
- Experienced management team with expertise in oncology drug development.
About AVEO
AVEO Pharmaceuticals, Inc., originally incorporated in 2001 and formerly known as GenPath Pharmaceuticals, is a biopharmaceutical company headquartered in Boston, Massachusetts, dedicated to improving the lives of cancer patients. The company focuses on the development and commercialization of targeted therapies for various types of cancer. AVEO's lead product, FOTIVDA (tivozanib), is an oral, once-daily, vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) approved for the treatment of adult patients with advanced renal cell carcinoma (RCC). Beyond FOTIVDA, AVEO is actively developing a pipeline of other oncology candidates. This includes Ficlatuzumab, a humanized IgG1 monoclonal antibody targeting hepatocyte growth factor (HGF), currently in Phase II clinical trials for squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia. AVEO is also advancing AV-203, a humanized IgG1 monoclonal antibody targeting human ErbB3, and AV-380, a humanized IgG1 inhibitory monoclonal antibody targeting cachexia, both in Phase I clinical trials. The company's preclinical programs include AV-353, which targets the Notch 3 pathway. AVEO has established strategic collaborations with companies such as CANbridge Life Sciences Ltd., EUSA Pharma (UK) Limited, Novartis International Pharmaceutical Ltd., and AstraZeneca PLC, to expand the reach and development of its oncology portfolio.
What They Do
- Develop and commercialize medicines for cancer patients.
- Market FOTIVDA for the treatment of renal cell carcinoma (RCC).
- Develop tivozanib for RCC, HCC, immunologically cold tumors, and CCA.
- Conduct clinical trials for Ficlatuzumab in squamous cell carcinoma, pancreatic cancer, and acute myeloid leukemia.
- Develop AV-203 for treating human ErbB3.
- Develop AV-380 for the treatment or prevention of cachexia.
- Conduct preclinical research on AV-353 that targets the Notch 3 pathway.
Business Model
- Develop and commercialize proprietary oncology drugs.
- Generate revenue through sales of FOTIVDA and potential future products.
- Collaborate with pharmaceutical companies to expand pipeline and market reach.
- Out-license or co-develop certain assets to share risk and generate revenue.
Industry Context
AVEO Pharmaceuticals operates within the competitive biotechnology industry, which is characterized by high R&D costs, lengthy development timelines, and stringent regulatory requirements. The oncology market is a significant driver within the biotechnology sector, with increasing demand for targeted therapies and personalized medicine. AVEO's focus on developing and commercializing cancer medicines positions it to capitalize on this trend. Competitors include companies developing similar targeted therapies or immunotherapies for cancer. The company's strategic collaborations and focus on specific cancer subtypes differentiate it within the crowded landscape.
Key Customers
- Cancer patients suffering from renal cell carcinoma (RCC).
- Healthcare providers who prescribe cancer treatments.
- Hospitals and oncology clinics that administer cancer therapies.
- Pharmaceutical companies that partner with AVEO for drug development and commercialization.
Financials
Chart & Info
AVEO Pharmaceuticals, Inc. (AVEO) stock price: $15.00 (+0.00, +0.00%)
Latest News
-
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2022
benzinga · Oct 24, 2022
-
Why fuboTV Shares Are Trading Higher By 11%; Here Are 22 Stocks Moving Premarket
benzinga · Oct 18, 2022
-
Earnings Scheduled For August 4, 2022
benzinga · Aug 4, 2022
-
Stocks That Hit 52-Week Lows On Friday
· Feb 28, 2020
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AVEO.
Price Targets
Wall Street price target analysis for AVEO.
MoonshotScore
What does this score mean?
The MoonshotScore rates AVEO's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2022
Why fuboTV Shares Are Trading Higher By 11%; Here Are 22 Stocks Moving Premarket
Earnings Scheduled For August 4, 2022
Stocks That Hit 52-Week Lows On Friday
What Investors Ask About AVEO Pharmaceuticals, Inc. (AVEO)
What does AVEO Pharmaceuticals, Inc. do?
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing targeted therapies for cancer patients. Its lead product, FOTIVDA (tivozanib), is an oral, once-daily, vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) approved for the treatment of adult patients with advanced renal cell carcinoma (RCC). The company also has a pipeline of other oncology candidates in various stages of clinical development, including Ficlatuzumab, AV-203, and AV-380. AVEO aims to improve patient outcomes by developing innovative therapies that address unmet needs in cancer treatment.
Is AVEO stock worth researching?
AVEO stock presents a mixed investment profile. The company has a commercially available product in FOTIVDA and a promising pipeline, which could drive future growth. The high gross margin of 87.8% is also attractive. However, the company is currently unprofitable, as reflected in its negative P/E ratio. Investors should carefully consider the risks associated with drug development and regulatory approvals before investing. Positive clinical trial results and successful commercialization of pipeline candidates could significantly increase the stock's value.
What are the main risks for AVEO?
The main risks for AVEO include clinical trial failures, regulatory delays or non-approval of new therapies, competition from other cancer treatments, and dependence on the success of FOTIVDA. The biotechnology industry is inherently risky, with high R&D costs and uncertain outcomes. AVEO's future success depends on its ability to successfully develop and commercialize its pipeline candidates. Patent expirations and generic competition also pose a threat to the company's revenue stream.
What are the key factors to evaluate for AVEO?
AVEO Pharmaceuticals, Inc. (AVEO) currently holds an AI score of 69/100, indicating moderate score. Key strength: Approved product (FOTIVDA) generating revenue.. Primary risk to monitor: Potential: Clinical trial failures for pipeline candidates.. This is not financial advice.
How frequently does AVEO data refresh on this page?
AVEO prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven AVEO's recent stock price performance?
Recent price movement in AVEO Pharmaceuticals, Inc. (AVEO) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Approved product (FOTIVDA) generating revenue.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider AVEO overvalued or undervalued right now?
Determining whether AVEO Pharmaceuticals, Inc. (AVEO) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying AVEO?
Before investing in AVEO Pharmaceuticals, Inc. (AVEO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Stock data pending update, which may impact financial metrics.
- Future success is dependent on clinical trial outcomes and regulatory approvals.